Medication info
Daehwa Acyclovir Tablet

Daehwa Acyclovir Tablet

Prescription medicationTablet
Ingredient · strength
Acyclovir›200mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Pale blue round tablet
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201307939 · Approved 2013.06.28 · Insurance code 645604250

Summary

Main use
Treatment and prevention of herpes simplex, treatment of herpes zoster, and treatment of chickenpox in children 2 years of age and older
Who uses it
Adults · Children
Adult dosage
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. In severe primary infections, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) It is preferable to start treatment as soon as possible after infection; in recurrent cases, treatment should preferably begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2 ~ 3 times daily, after confirming its efficacy. 3) To assess the natural course of the disease, treatment should be periodically discontinued and assessed every 6 ~ 12 months in patients receiving long-term treatment. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this drug per dose 5 times daily at approximately 4-hour intervals, except during sleeping hours, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunocompromise or gastrointestinal absorption disorders. 3) It is preferable to start treatment as soon as possible after infection; the earlier the treatment, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience adverse reactions affecting the neuropsychiatric system; therefore, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer this drug at 200 mg every 12 hours. 2. Treatment of herpes zoster virus infections 1) In patients with creatinine clearance less than 10 mL/min, it is preferable to reduce the dose to 800 mg per dose twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL/min, it is preferable to reduce the dose to 800 mg per dose 3 times daily, at approximately 8-hour intervals.
Children's dosage
○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients 1) Age 2 years and older: Same as the adult dose. 2) Under 2 years: Administer 1/2 of the adult dose. 3) There are currently no definitive data on the prevention of herpes simplex virus infections in patients with normal immune function. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg/kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. The earlier treatment is started after the chickenpox rash appears, the better; administer within 24 hours after the rash appears whenever possible.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes simplex, treatment of herpes zoster, and treatment of chickenpox in children 2 years of age and older

  • Genital herpes
  • herpes simplex virus infections of skin and mucous membranes
  • herpes zoster virus infections
  • pain in acute stages
  • chickenpox
View approved original text

This medication is used to treat and prevent herpes simplex virus infections that occur in the skin and mucous membranes, including initial and recurrent genital herpes. It is also effective in treating herpes zoster virus infections, especially helping to relieve acute phase pain. However, the effectiveness for post-herpetic neuralgia is not yet conclusively established. It is suitable for treating chickenpox in children aged 2 years and older. This drug is effectively used for the treatment and prevention of various infections.

Dosage and Administration

Adult dosage

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. In severe primary infections, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) It is preferable to start treatment as soon as possible after infection; in recurrent cases, treatment should preferably begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2 ~ 3 times daily, after confirming its efficacy. 3) To assess the natural course of the disease, treatment should be periodically discontinued and assessed every 6 ~ 12 months in patients receiving long-term treatment. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this drug per dose 5 times daily at approximately 4-hour intervals, except during sleeping hours, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunocompromise or gastrointestinal absorption disorders. 3) It is preferable to start treatment as soon as possible after infection; the earlier the treatment, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience adverse reactions affecting the neuropsychiatric system; therefore, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer this drug at 200 mg every 12 hours. 2. Treatment of herpes zoster virus infections 1) In patients with creatinine clearance less than 10 mL/min, it is preferable to reduce the dose to 800 mg per dose twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL/min, it is preferable to reduce the dose to 800 mg per dose 3 times daily, at approximately 8-hour intervals.

Children's dosage

○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients 1) Age 2 years and older: Same as the adult dose. 2) Under 2 years: Administer 1/2 of the adult dose. 3) There are currently no definitive data on the prevention of herpes simplex virus infections in patients with normal immune function. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg/kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. The earlier treatment is started after the chickenpox rash appears, the better; administer within 24 hours after the rash appears whenever possible.

Precautions

This medication should not be used in patients who are hypersensitive to the drug itself or its components. Patients with impaired renal function may experience central nervous system adverse reactions, so caution is advised. Patients with reduced liver function should be administered with caution as liver function may further deteriorate. Use in infants and children should be approached with caution, especially in neonates or low birth weight infants, where safety has not been established, and should only be administered when necessary. Elderly patients often have reduced renal function, which may increase drug concentration in the blood, so dosage and interval should be adjusted with caution. Serious allergic reactions such as anaphylactic shock may rarely occur, so symptoms should be carefully monitored during administration. If hypersensitivity reactions such as rash, fever, blisters, hives occur, administration should be stopped immediately, and appropriate measures should be taken. Conditions such as hair loss, erythema multiforme, and severe skin diseases may develop, so consultation with a doctor is necessary if symptoms appear. Central nervous system symptoms such as altered consciousness, confusion, hallucinations, and seizures may occur, especially more frequently in elderly patients or those with renal impairment. Renal-related adverse reactions such as renal function impairment, hematuria, and proteinuria may occur, so renal status should be monitored periodically. Blood and lymphatic system abnormalities may occur, so if symptoms like bleeding, anemia, or leukopenia arise, immediate medical consultation is required. Liver function abnormalities, jaundice, and hepatitis may occur, so regular liver function tests are recommended. Gastrointestinal symptoms such as gastritis, vomiting, and diarrhea may occur, and if symptoms are severe, administration should be discontinued. Systemic symptoms such as fever, muscle weakness, and headache may occur, so if any unusual symptoms arise, notify a doctor. Musculoskeletal pain or arthralgia may occur. Adverse cardiovascular effects such as arrhythmia, blood pressure changes, chest pain should be handled with care. Urinary anomalies such as urinary obstruction or difficulty urinating may rarely arise. Sufficient hydration is important when using this medication, especially to prevent dehydration when high doses are administered. To enhance therapeutic effect, it is advisable to start treatment as soon as possible, within 5 days after the onset of shingles skin symptoms, and within 3 days for chickenpox. Patients with impaired immune function may consider intravenous treatment. Caution is necessary when driving or operating hazardous machinery due to the potential for altered consciousness, and patients with reduced renal function should exercise additional caution. This medication may interact with other drugs, particularly those affecting renal function, increasing the risk of renal toxicity. Women who are pregnant or may become pregnant should carefully weigh the benefits and risks of treatment, and breastfeeding should be halted as the drug components can be passed in breast milk.

Side effects

  • Anaphylactic shock
  • anaphylactoid reaction
  • hypotension
  • respiratory distress
  • tightness in the chest
  • photosensitivity reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 118 more
  • urticarial erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • concentration difficulty
  • aggressive behavior
  • depersonalization
  • agitation
  • dyskinesia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • convulsions
  • drowsiness
  • tremors
  • excitement
  • forgetfulness
  • insomnia
  • anxiety
  • talking to oneself
  • abnormal sensations
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • dizziness
  • renal failure
  • crystalluria
  • elevated BUN
  • increased serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • hemorrhage
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • upper abdominal pain
  • stomach pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • fatigue
  • general malaise
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • elevated blood pressure
  • lowered blood pressure
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glucosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorder
  • hair loss
  • sweating
  • hyponatremia
  • hypoproteinemia
  • elevated total cholesterol levels
  • elevated triglycerides
  • increased serum potassium levels
  • decreased serum albumin levels
  • agitation
  • coma
  • convulsions
  • somnolence
  • confusion
  • hallucinations
  • excitement
  • seizures
  • state of coma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to ensure the drug's efficacy remains safely intact for a long duration.

Appearance and packaging

Appearance

Pale blue round tablet

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.